CoChat
Sign Up
Cited by 200

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Targeted nanoparticles for detecting and treating cancer

Sunderland, Christopher J., Steiert, Matthias, Talmadge, James E., Derfus, Austin M., Barry, Stephen E.·2006·Drug Development Research
DOI 10.1002/ddr.20069
Open this paper in CoChat — free account

Abstract

Enabled by their size and supramolecular structures, nanoparticles (that is, particles of approximately 10 to 100 nanometers) promise to be particularly capable agents in the detection, diagnosis, and treatment of cancer. When loaded with chemotherapeutic agents, nanoparticle delivery to cancerous tissues relative to healthy tissues may be favorably biased by size and through the attachment of targeting ligands to the surface of the particle. Nanoparticles may be made from a variety of materials, and in addition to chemotherapeutic payloads, nanoparticles can incorporate non‐bioactive elements useful as diagnostic and device agents. For example, the inclusion of iron oxide colloids enables nanoparticle use as magnetic resonance imaging (MRI) contrast agents, and also, through the application of an alternating magnetic field (AMF), enables the particle to generate enough heat to be used for hyperthermic therapeutic applications. In this report, we also introduce novel Magnetic Nanoparticle Hydro‐Gel (MagNaGel TM) materials comprised of chemotherapeutic agents, iron oxide colloids, and targeting ligands. MagNaGel particles were fabricated in the 20‐ to 40‐nm size range with very narrow size dispersion. These particles demonstrate high (>10 wt %) chemotherapeutic loading, tumor‐associated biomolecular binding, good magnetic susceptibility, and attractive toxicity and circulation profiles in mouse models. Looking forward, the convergence of drug and device on the nano‐scale promises treatment modalities that cannot be practiced through traditionally distinct drug and device combinations. MagNaGel nanoparticles are drug‐device hybrids that, when used in conjunction with diagnostic MRI and inductive heating, may play a key role in new and powerful cancer treatment regimens. Drug Dev. Res. 67:70–93, 2006. © 2006 Wiley‐Liss, Inc.

Overview

Integrity signals

Registry

Crossref · 10.1002/ddr.20069

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 3 references

Research works printed but not linked: 115

  1. 10.1038/nrc903 · DOI
  2. 10.1053/j.seminoncol.2004.08.001 · DOI
  3. 10.1080/02656730500110155 · DOI
  4. 10.1126/science.1310359 · DOI
  5. 10.1002/polc.5070160645 · DOI
  6. 10.1124/jpet.105.084145 · DOI
  7. 10.1517/14712598.4.11.1777 · DOI
  8. 10.1021/bc034153y · DOI
  9. Beer AJ, 2005, Biodistribution and pharmacokinetics of the {alpha}v{beta}3‐selective tracer 18F‐galacto‐RGD in cancer patients, J Nucl Med, 46, 1333
  10. 10.1016/j.ijpharm.2004.12.021 · DOI
  11. 10.1002/mrm.10066 · DOI
  12. 10.1002/ijc.10158 · DOI
  13. 10.1038/sj.onc.1205793 · DOI
  14. 10.1016/S1359-6446(03)02806-X · DOI
  15. 10.1097/00004424-199406001-00004 · DOI
  16. 10.1016/0041-008X(71)90312-7 · DOI
  17. 10.2165/00003088-199733040-00001 · DOI
  18. Chen FM, 1990, Localization of monoclonal antibody TNT‐1 in experimental kidney infarction of the mouse, FASEB J, 4, 3033, 10.1096/fasebj.4.12.2394321 · DOI
  19. 10.1016/j.nucmedbio.2003.07.003 · DOI
  20. 10.1093/jnci/83.3.200 · DOI
  21. 10.1007/s002470050296 · DOI
  22. 10.1148/radiol.2293021045 · DOI
  23. 10.1517/14712598.4.9.1445 · DOI
  24. 10.1148/radiol.2292021007 · DOI
  25. 10.1081/CNV-200027148 · DOI
  26. 10.1007/s10147-003-0369-x · DOI
  27. Drummond DC, 1999, Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors, Pharmacol Rev, 51, 691, 10.1016/S0031-6997(24)01426-1 · DOI
  28. 10.1038/nrd1088 · DOI
  29. Fidler IJ, 1984, The evolution of biologic diversity in metastases, Transplant Proc, 16, 370
  30. 10.1039/b503425f · DOI
  31. Fujimori K, 1990, A modeling analysis of monoclonal antibody percolation through tumors: a binding‐site barrier, J Nucl Med, 31, 1191
  32. 10.3109/10611869409015905 · DOI
  33. 10.2165/00003495-199700544-00005 · DOI
  34. 10.1016/S0959-8049(01)00171-X · DOI
  35. Ghobrial I, 2004, Radioimmunotherapy: a new treatment modality for B‐cell non‐Hodgkin's lymphoma, Oncology, 18, 623
  36. 10.1097/00000658-195710000-00007 · DOI
  37. 10.1016/j.jmmm.2005.02.020 · DOI
  38. Graff CP, 2003, Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention, Cancer Res, 63, 1288
  39. 10.1021/bc040297g · DOI
  40. 10.1016/S1359-6446(05)03369-6 · DOI
  41. 10.1016/j.bmc.2003.09.023 · DOI
  42. 10.1358/dot.2005.41.2.882662 · DOI
  43. 10.1021/bk-1997-0680 · DOI
  44. 10.1016/S0142-9612(03)00343-0 · DOI
  45. 10.1049/ip-nbt:20055018 · DOI
  46. 10.1073/pnas.2232479100 · DOI
  47. Hong RL, 1999, Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C‐26 tumor‐bearing mice: is surface coating with polyethylene glycol beneficial?, Clin Cancer Res, 5, 3645
  48. 10.1038/nrc1609 · DOI
  49. 10.1038/sj.cgt.7700791 · DOI
  50. 10.1021/mp0500014 · DOI
  51. 10.1016/S0304-8853(99)00088-8 · DOI
  52. 10.1002/(SICI)1522-2594(200005)43:5<633::AID-MRM3>3.0.CO;2-R · DOI
  53. 10.1007/s00280-004-0941-8 · DOI
  54. Kong G, 2000, Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release, Cancer Res, 60, 6950
  55. Kong G, 2000, Hyperthermia enables tumor‐specific nanoparticle delivery: effect of particle size, Cancer Res, 60, 4440
  56. Kong G, 2001, Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature, Cancer Res, 61, 3027
  57. 10.1016/S0168-3659(03)00340-7 · DOI
  58. 10.3109/02656739509022491 · DOI
  59. 10.1038/nm720 · DOI
  60. 10.1016/S0169-409X(02)00015-7 · DOI
  61. 10.1021/bc990076o · DOI
  62. 10.1021/nl050127s · DOI
  63. 10.1016/j.addr.2004.02.003 · DOI
  64. 10.1200/JCO.2005.00.802 · DOI
  65. 10.1016/S0065-2571(00)00013-3 · DOI · Paper page
  66. 10.1016/S0168-3659(99)00246-1 · DOI
  67. 10.1158/0008-5472.CAN-03-2485 · DOI
  68. 10.1016/S0169-409X(99)00043-5 · DOI
  69. Matsumura Y, 1987, General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics], Gan To Kagaku Ryoho, 14, 821
  70. 10.1002/ddr.20070 · DOI
  71. 10.1002/(SICI)1522-2594(199907)42:1<141::AID-MRM19>3.0.CO;2-I · DOI
  72. 10.1016/S0168-3659(01)00319-4 · DOI · Paper page
  73. 10.1007/s004180100289 · DOI
  74. 10.1034/j.1399-3011.2000.00723.x · DOI
  75. 10.1179/joc.2004.16.Supplement-1.77 · DOI
  76. 10.1016/0005-2736(92)90112-Y · DOI
  77. Needham D, 2000, A new temperature‐sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model, Cancer Res, 60, 1197
  78. 10.1016/S1359-6446(05)03420-3 · DOI
  79. 10.1016/0024-3205(96)00221-4 · DOI
  80. 10.1016/S0168-3659(01)00315-7 · DOI
  81. 10.1016/S0960-894X(99)00661-7 · DOI
  82. 10.1038/309030a0 · DOI
  83. 10.1081/LPR-120017486 · DOI
  84. 10.1200/JCO.1997.15.10.3185 · DOI
  85. 10.1016/S0169-409X(96)00404-8 · DOI
  86. 10.1016/S0168-3659(01)00320-0 · DOI
  87. 10.1634/theoncologist.8-suppl_2-3 · DOI
  88. 10.1634/theoncologist.10-3-205 · DOI
  89. 10.1006/jtbi.1998.0792 · DOI
  90. 10.1126/science.2821619 · DOI
  91. 10.1054/bjoc.2001.2026 · DOI
  92. 10.1021/bc020091k · DOI
  93. 10.1081/LPR-120004785 · DOI
  94. 10.1016/S0168-3659(03)00240-2 · DOI
  95. 10.1002/ijc.10727 · DOI
  96. 10.1016/S0167-8140(98)00098-X · DOI
  97. 10.1038/bjc.1991.190 · DOI
  98. 10.1002/mrm.1910290506 · DOI
  99. 10.2174/1381612043453009 · DOI
  100. 10.1186/1476-5926-2-S1-S22 · DOI
  101. 10.1182/blood-2004-01-0177 · DOI
  102. Talmadge JE, 1984, Development of biological diversity and susceptibility to chemotherapy in murine cancer metastases, Cancer Res, 44, 3801
  103. Tucker GC, 2003, Alpha v integrin inhibitors and cancer therapy, Curr Opin Invest Drugs, 4, 722
  104. 10.1148/radiology.218.2.r01fe37562 · DOI
  105. 10.1021/ac0486140 · DOI
  106. 10.1080/10611860400011869 · DOI
  107. 10.1182/blood.V97.10.3197 · DOI
  108. 10.1016/S1359-6446(05)03477-X · DOI
  109. 10.1002/mrm.20074 · DOI
  110. 10.1056/NEJM199101033240101 · DOI
  111. 10.1212/WNL.56.9.1188 · DOI
  112. Weitman SD, 1992, Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis, Cancer Res, 52, 6708
  113. 10.1016/S0959-8049(01)00074-0 · DOI
  114. 10.1002/cncr.21128 · DOI
  115. Winter PM, 2003, Molecular imaging of angiogenesis in nascent Vx‐2 rabbit tumors using a novel alpha(v)beta3‐targeted nanoparticle and 1.5 tesla magnetic resonance imaging, Cancer Res, 63, 5838

Cited by

Sorted by citations

See all 200

Metadata

Authors
Sunderland, C. J., Steiert, M., Talmadge, J. E., Derfus, A. M., & Barry, S. E.
Venue
Drug Development Research
Publisher
Wiley
Published
2006-01
Volume
67
Issue
1
Pages
70-93
ISSN
  • 0272-4391
  • 1098-2299
DOI
10.1002/ddr.20069
Cited by
200
References
3
Language
en
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 130 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted nanoparticles for detecting and treating cancer. https://app.cochat.ai/papers/10.1002/ddr.20069
The paper
Sunderland, C. J., Steiert, M., Talmadge, J. E., Derfus, A. M., & Barry, S. E. (2006). Targeted nanoparticles for detecting and treating cancer. Drug Development Research. https://doi.org/10.1002/ddr.20069